HK Stock Market Move | HBM HOLDINGS-B(02142) rises more than 7% again, up 180% in the past month, recently reached a $1 billion overseas cooperation and licensing agreement.

HBM HOLDINGS-B(02142) rose over 7% today, with a cumulative increase of 180% since December 17. As of the time of writing, it rose by 7.05%, reaching HK$3.19, with a turnover of HK$13.7062 million. In terms of news, Hepalink recently announced that it has signed a licensing agreement with Windward Bio for HBM9378/SKB378. Windward Bio has been granted exclusive rights to research, develop, produce, and commercialize HBM9378/SKB378 globally (excluding Greater China and certain Southeast Asian and West Asian countries). The licensor is entitled to receive up to a total of $970 million in upfront and milestone payments, as well as single to double-digit percentage tiered royalty payments based on net sales. In addition, Hepalink announced earlier this month that the company has decided to exercise its repurchase authorization and repurchase shares on the open market based on market conditions, using up to HK$40 million for the proposed share repurchase. The company may further repurchase shares within the applicable authorization range depending on market conditions. The Board of Directors believes that the current market trading price of the company's stock significantly undervalues the company's intrinsic value and business prospects.